This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Small-Cap Winners & Losers

Despite a few leaping tech names, small-cap stocks once again slunk behind the broad indices Wednesday.

But BladeLogic (BLOG), a data-center automation-software company, catapulted 45.2% to $24.69 after its initial public offering of 5 million shares, 3.94 million of which are being sold by the company itself. Underwriters have an option for another 750,000 shares.

Supertex (SUPX), a Sunnyvale, Calif., semiconductor firm, jumped 13.6% despite coming in just under top- and bottom-line expectations for the fiscal first quarter, and semiconductor-equipment maker Semitool (SMTL) was higher after posting a small break-even loss for the quarter ended June 30 on revenue of $46.6 million. Thomson Financial's estimates had it losing 2 cents a share, and two analysts predicted sales of $45.5 million.

Supertex shares were up $4.41 to $36.91 as Montana-based Semitool gained 13% to $10.20, each in support of the Russell 2000, which was up 0.2% to 813.07. The S&P SmallCap 600, which counts Supertex as a member, was up marginally at 426.99.

GPC Biotech (GPCB) was among Wednesday's worst losers overall, however, after a Food and Administration advisory panel unanimously recommended that the FDA wait for more information before approving its prostate-cancer drug satraplatin.

Shares of the Germany-based company plummeted 34.6% to $13.32 as partner Spectrum Pharmaceuticals (SPPI) slid 17.1% to $3.98. Pharmion (PHRM), which has some commercialization rights to the drug, gave up 1.2% to $24.32.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
SUPX $32.98 0.00%
TGEN $4.07 0.00%
JACK $87.47 0.00%
AAPL $126.44 0.00%
FB $87.28 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs